Clinical trials
Systemic Light Chain Amyloidosis clinical trials
Below are recruiting systemic light chain amyloidosis clinical trials, each written for real people, not researchers. We’re tracking 17 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06376214Recruiting
Daratumumab for newly diagnosed light chain amyloidosis
This trial tests the drug daratumumab in people newly diagnosed with light chain amyloidosis that affects the heart, kidney, or liver. The goal is to see if daratumumab can help control the disease. Eligibility depends on your disease stage and overall health.
Nanjing, JiangsuAges 18–75 - NCT07388602RecruitingPhase 3
New drug combo for newly diagnosed AL amyloidosis
This trial tests a new drug (SCTC21C) combined with three standard chemotherapy medicines for people who have just been diagnosed with AL amyloidosis. The goal is to see if adding the new drug helps reduce the abnormal protein deposits better than the standard treatment alone.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07266116RecruitingPhase 1/Phase 2
TQB2934 injection for light chain amyloidosis
This trial tests a new injectable drug called TQB2934 for people with systemic light chain amyloidosis. It aims to see if the drug is safe and effective for those whose disease has come back or gotten worse after previous treatment.
Beijing, Beijing MunicipalityAges 18–80 - NCT07232459Recruiting
PET imaging for amyloidosis in the heart
This study tests a new PET imaging tracer called [18F]FT8 to see if it can better detect amyloid protein buildup in the heart. It may help doctors diagnose and monitor cardiac amyloidosis more accurately.
Hefei, AnhuiAges 18 years+ - NCT07224672RecruitingPhase 2
Study of a drug combo for newly diagnosed AL amyloidosis
This trial tests a combination of four drugs (belantamab mafodotin, cyclophosphamide, bortezomib, and dexamethasone) for people newly diagnosed with AL amyloidosis who cannot have a stem cell transplant. The goal is to see if this combination is safe and effective at stopping the abnormal proteins from damaging your organs.
Rochester, MinnesotaAges 18 years+ - NCT07215494Recruiting
AL Amyloidosis: Testing for Hidden Disease After Transplant
This study looks for 'minimal residual disease' (tiny traces of amyloid after treatment) in people with AL amyloidosis who have had a stem cell transplant. It helps doctors understand if more treatment is needed.
Beijing, Beijing MunicipalityAges 18–70 - NCT07151690RecruitingPhase 2
BCMA/CD3 bispecific antibody for newly diagnosed AL amyloidosis
This trial tests a new bispecific antibody treatment for people newly diagnosed with AL amyloidosis. The drug targets BCMA on myeloma cells and CD3 on immune cells to help your body fight the disease.
TianjinAges 18 years+ - NCT07110844RecruitingPhase 2
Teclistamab with Daratumumab for Newly Diagnosed AL Amyloidosis
This trial tests a combination of two drugs (teclistamab and daratumumab) for people with AL amyloidosis who have not had prior treatment. The goal is to see if this combination can safely and effectively reduce the abnormal protein deposits in organs.
Boston, MassachusettsAges 18–100 - NCT06971380RecruitingPhase 2
CAR-T therapy for multiple myeloma and amyloidosis
This trial tests a new CAR-T cell treatment (HBI0101) for people with multiple myeloma or light-chain amyloidosis that has come back or stopped responding to other treatments. The therapy uses your own immune cells to fight cancer, and the goal is to see if it can help control the disease.
JerusalemAges 18 years+ - NCT06292780RecruitingPhase 1/Phase 2
Testing linvoseltamab for AL amyloidosis that came back
This trial tests a new drug called linvoseltamab for people with AL amyloidosis that has returned or is not responding to treatment. It aims to see if the drug is safe and helps control the disease.
Duarte, CaliforniaAges 18 years+ - NCT06205953Recruiting
European registry for newly diagnosed AL amyloidosis
This study collects information and samples from people newly diagnosed with AL amyloidosis who have not yet received treatment. It aims to improve how this rare disease is diagnosed and managed across Europe.
HeidelbergAges 18–99 - NCT06158854RecruitingPhase 1/Phase 2
Study of etentamig (ABBV-383) for AL amyloidosis
This study tests a new drug called etentamig (ABBV-383) given through a vein to see if it can control disease activity in people with AL amyloidosis who have already tried other treatments. It may help if your disease has progressed or is not responding well to prior therapies.
Miami, FloridaAges 18 years+ - NCT05951816RecruitingPhase 1
Imaging study for amyloidosis in heart and body
This study tests a new imaging agent (99mTc-p5+14) that helps doctors see amyloid deposits in the body, especially in the heart. It is for healthy volunteers and people with AL or ATTR amyloidosis that has affected the heart.
Knoxville, TennesseeAges 18 years+ - NCT05652335RecruitingPhase 1
JNJ-79635322 for hard-to-treat myeloma or amyloidosis
This Phase 1 study tests how safe and how well JNJ-79635322 works in people with multiple myeloma that has come back or is resistant to treatment, or AL amyloidosis that has already been treated. It may help by targeting cancer cells and abnormal proteins driving these diseases.
Duarte, CaliforniaAges 18 years+ - NCT06342466RecruitingPhase 2
Study of bortezomib, pomalidomide, and dexamethasone for AL amyloidosis
This trial tests a combination of three drugs—bortezomib, pomalidomide, and dexamethasone—to see how well they work for people with AL amyloidosis, a condition where abnormal proteins build up in organs. You may join if you are newly diagnosed or have had prior treatment and your organs are affected.
Beijing, Beijing MunicipalityAges 18–90 - NCT06768489RecruitingPhase 1
Combination therapy for multiple myeloma and related conditions
This trial tests a new drug combined with other medicines for people with multiple myeloma, a related condition called AL amyloidosis, or high-risk smoldering multiple myeloma. It aims to see if the combination is safe and effective.
Denver, ColoradoAges 18 years+ - NCT07585760RecruitingPhase 2
Two-drug treatment for newly diagnosed myeloma with kidney problems
This trial tests a combination of two drugs, CM336 and isatuximab, for people newly diagnosed with multiple myeloma who also have kidney problems caused by the disease. The goal is to see if this combination can help control the myeloma while also improving kidney function.
TianjinAges 18–80
Hear when a new Systemic Light Chain Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for systemic light chain amyloidosis?
- Yes. Clin2 currently lists 17 recruiting systemic light chain amyloidosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a systemic light chain amyloidosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a systemic light chain amyloidosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.